Mannkind (MNKD) Total Non-Current Liabilities (2012 - 2026)
Mannkind's (MNKD) quarterly Total Non-Current Liabilities came in at $798.5 million in Q1 2026, up 150.64% year-on-year from $318.6 million in Q1 2025, and down 4.73% on a QoQ basis from $838.1 million in Q4 2025.
Mannkind (MNKD) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends
Mannkind (MNKD) has 15 years of Total Non-Current Liabilities data on file, last reported at $798.5 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities rose 150.64% year-over-year to $798.5 million in Q1 2026; TTM through Mar 2026 was $798.5 million, a 150.64% increase from a year earlier, with the FY2025 full-year figure at $838.1 million, up 159.42% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $798.5 million, down from $838.1 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for MNKD reached as high as $838.1 million in Q4 2025 and fell as low as -$78.3 million in Q4 2023.
- Historically, Total Non-Current Liabilities has averaged $458.7 million across 5 years, with a median of $526.7 million in 2022.
- Across the five-year window, Total Non-Current Liabilities slumped 12948.33% in 2023 and soared 512.64% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at -$600000.0 in 2022, then slumped by 12948.33% to -$78.3 million in 2023, then surged by 512.64% to $323.1 million in 2024, then surged by 159.42% to $838.1 million in 2025, then slipped by 4.73% to $798.5 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $798.5 million in Q1 2026, $838.1 million in Q4 2025, and $521.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Mannkind | 1.20 Bn | 1.07 Bn | 82.66 Mn | 798.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 798.45 Mn |
| Dec 31, 2025 | 838.09 Mn |
| Sep 30, 2025 | 521.59 Mn |
| Jun 30, 2025 | 430.54 Mn |
| Mar 31, 2025 | 318.56 Mn |
| Dec 31, 2024 | 323.06 Mn |
| Sep 30, 2024 | 567.63 Mn |
| Jun 30, 2024 | 563.02 Mn |
| Mar 31, 2024 | 710.55 Mn |
| Dec 31, 2023 | -78.29 Mn |
| Sep 30, 2023 | 560.41 Mn |
| Jun 30, 2023 | 323.01 Mn |
| Mar 31, 2023 | 552.92 Mn |
| Dec 31, 2022 | -600,000.00 |
| Sep 30, 2022 | 526.71 Mn |
| Jun 30, 2022 | 309.35 Mn |
| Mar 31, 2022 | 533.33 Mn |
| Dec 31, 2021 | 525.56 Mn |
| Sep 30, 2021 | 417.89 Mn |
| Jun 30, 2021 | 431.03 Mn |